Cystic Pancreatic Neuroendocrine Neoplasms : A Multicenter International Cohort Study

S. Gaujoux,Sofia Westermark,M. Sund,A. Kaeding,A. Schmidt,L. Maggino

DOI: https://doi.org/10.1159/000498996

Abstract:Introduction: Natural history of cystic pancreatic neuroendocrine neoplasms (cPanNENs) is unknown, and their clinical management remains unclear. An observational strategy for asymptomatic cPanNENs ...

Medicine

What problem does this paper attempt to address?

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Ren-Chao Zhang,Yi-Ping Mou,Xiao-Wu Xu,Jia-Fei Yan,Qi-Long Chen

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2013.09.004

2013-01-01

Abstract:OBJECTIVE:To analyze the prognostic factors of pancreatic neuroendocrine neoplasms (PNEN).METHODS:Clinical data of 61 patients with PNEN from March 1992 to December 2012 was retrospectively analyzed. There were 23 male and 38 female patients, with a median age of 52 years (ranged from 22 to 68 years). Forty-one patients were non-functional tumors, and 20 patients were functional tumors. Fifty-nine patients received operation, 13 (22.0%) patients underwent laparoscopic operation, 2 patients underwent puncture biopsy under CT guidance. Survival was analyzed with the Kaplan-Meier method.RESULTS:Among these patients, 53 (86.9%) patients underwent curative resection. The cases of grade G1, G2, G3 were 41 (67.2%), 9 (14.8%), 11 (18.0%), respectively. The cases of stageI, II, III, IV were 47 (77.0%), 7 (11.5%), 2 (3.3%), 5 (8.2%), respectively. Liver metastasis, neural invasion were found in 5 cases (8.2%), 5 cases (8.2%), respectively. The median follow-up period was 40 months (ranged from 3 to 209 months). The overall 1-, 3-, 5-year survival rates were 92.0%, 89.7%, 86.3%, respectively. Univariate analysis showed WHO classification (χ(2) = 18.503), TNM staging system (χ(2) = 23.401), liver metastasis (χ(2) = 18.606), neural invasion (χ(2) = 10.091), resection status (χ(2) = 25.514) were prognostic factors of PNEN (all P = 0.000).CONCLUSIONS:Surgical resection in PNEN results in long-term survival. WHO classification, TNM staging, resection status are effective in predicting the prognosis of PNEN. Liver metastasis, neural invasion predicted poor prognosis.
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study

Stefano Partelli,John K. Ramage,Sara Massironi,Alessandro Zerbi,Hong Beom Kim,Patricia Niccoli,Francesco Panzuto,Luca Landoni,Ales Tomazic,Toni Ibrahim,Gregory Kaltsas,Emilio Bertani,Alain Sauvanet,Eva Segelov,Martyn Caplin,Jorgelina Coppa,Thomas Armstrong,Martin O. Weickert,Giovanni Butturini,Stefan Staettner,Florian Boesch,Mauro Cives,Carol Anne Moulton,Jin He,Andreas Selberherr,Orit Twito,Antonio Castaldi,Claudio Giovanni De Angelis,Sebastien Gaujoux,Hussein Almeamar,Andrea Frilling,Emanuel Vigia,Colin Wilson,Francesca Muffatti,Raj Srirajaskanthan,Pietro Invernizzi,Andrea Lania,Wooil Kwon,Jacques Ewald,Maria Rinzivillo,Chiara Nessi,Lojze M. Smid,Andrea Gardini,Marina Tsoli,Edgardo E. Picardi,Olivia Hentic,Daniel Croagh,Christos Toumpanakis,Davide Citterio,Emma Ramsey,Barbara Mosterman,Paolo Regi,Silvia Gasteiger,Roberta E. Rossi,Valeria Smiroldo,Jin-Young Jang,Massimo Falconi

DOI: https://doi.org/10.3389/fmed.2020.598438

IF: 3.9

2020-12-23

Frontiers in Medicine

Abstract:Introduction: The optimal treatment for small, asymptomatic, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN) is still controversial. European Neuroendocrine Tumor Society (ENETS) guidelines recommend a watchful strategy for asymptomatic NF-PanNEN <2 cm of diameter. Several retrospective series demonstrated that a non-operative management is safe and feasible, but no prospective studies are available. Aim of the ASPEN study is to evaluate the optimal management of asymptomatic NF-PanNEN ≤2 cm comparing active surveillance and surgery. Methods: ASPEN is a prospective international observational multicentric cohort study supported by ENETS. The study is registered in ClinicalTrials.gov with the identification code NCT03084770. Based on the incidence of NF-PanNEN the number of expected patients to be enrolled in the ASPEN study is 1,000 during the study period (2017–2022). Primary endpoint is disease/progression-free survival, defined as the time from study enrolment to the first evidence of progression (active surveillance group) or recurrence of disease (surgery group) or death from disease. Inclusion criteria are: age >18 years, the presence of asymptomatic sporadic NF-PanNEN ≤2 cm proven by a positive fine-needle aspiration (FNA) or by the presence of a measurable nodule on high-quality imaging techniques that is positive at 68 Gallium DOTATOC-PET scan. Conclusion: The ASPEN study is designed to investigate if an active surveillance of asymptomatic NF-PanNEN ≤2 cm is safe as compared to surgical approach.

medicine, general & internal
Clinical Features Of Patients With Pancreatic Neuroendocrine Neoplasms: A Retrospective Analysis Of 61 Cases In A Cancer Center

Panpan Zhang,Ming Lu,Xicheng Wang,Lin Shen,Jian Li,Jun Zhou,Xiaotian Zhang,Zhi Peng,Yanshuo Cao,Zuyao Yang,Jie Li

2017-01-01

Abstract:Objective: To assess the clinicopathological features of patients with pancreatic neuroendocrine neoplasms (pNENs) in relation with clinical outcomes. Methods: A total of 61 patients with pNENs were enrolled in this study. Patients' characteristics, treatment procedures, and clinical follow-up were retrospectively analyzed. Results: Among the 61 patients, 29 patients (47.5%) were men and 32 patients (52.5%) were women. 6 patients (9.8%) had functional pNENs and presented with diarrhea, flushing, sweating, palpitations or glucose abnormalities. At diagnosis, 31.1% (19/61) had a localized disease, 6.6% (4/61) presented with regional spread including lymph node metastases and/or extrapancreatic organ invasions, and 62.3% (38/61) had distant metastases. Liver was the most common site of metastasis. 58 cases were recorded with detailed pathological information, among which 42 patients (72.4%) were diagnosed as NET G1/G2, 16 patients (27.6%) were diagnosed as NEC G3. The chromogranin A (CgA) levels were elevated in the serum of patients with liver metastasis, unresectable tumors or a Ki-67 proliferative index >= 20%. The univariate analysis suggested that the WHO classification, stage, occurrence of liver metastasis and operative approaches were closely related to the prognosis of pNENs; while sex, age, tumor size and functional status were not. Conclusion: The pNENs are a heterogeneous group of neoplasms with diverse clinical manifestations and prognosis. Serum CgA is an indicator of tumor burden and proliferation. The WHO classification, stage, liver metastasis and operative approaches might closely relate to the prognosis of pNENs.
Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

ZHAO Ting,CHEN Jionghuang,CAO Liping

DOI: https://doi.org/10.3969/j.issn.1000-8179.2017.16.354

2017-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective: To investigate the clinical characteristics, diagnosis, treatment, and prognostic factors of pancreatic neuroendocrine neoplasms (PNENs). Methods: From August 2004 to August 2016, the clinical data of 63 patients with PNENs in the Sir Run Run Shaw Hospital, an affiliate of the Zhejiang University School of Medicine, were retrospectively analyzed. The data included age, gender, function, tumor location, tumor size, pathological characteristics, lymph nodes, metastasis, and treatment. Association of these factors with PNEN prognosis was proven by univariate analysis and multivariate analysis. Results: In our study, the patients' overall survival time was between 5 and 127 months; the median time was about 46.6 months. Moreover, the survival rates in three years and five years are 88.8％ and 84.1％ respectively. Univariate analysis showed that factors such as lymph node metastasis, liver metastasis, vascular invasion, TNM staging and pathological grading, and radical operation were associated with prognosis (P<0.05). We did not prove any of the factors to be an independent factor associated with poor short-term outcome by multivariate analysis. Conclusion: PNENs are rare low-grade malignant tumors with heterogeneity, which is why they can be erroneously diagnosed. AJCC TNM staging in 2017 and the WHO pathological classification in 2010 can actively guide the prognosis evaluation. The lymph node metastasis, liver metastasis,and vascular invasion affected the prognosis of PNENs. Patients with radical operation had improved prognosis.
Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature

A Amador Cano,F García,A Espinoza,N Bezies,E Herrera,J De Leija Portilla

DOI: https://doi.org/10.1016/j.ijscr.2012.10.018

Abstract:Introduction: Pancreatic neuroendocrine tumors (PNET) have an incidence of one per 100,000 individuals per year. They represent about 1-2% of all pancreatic tumors. PNETs are a heterogeneous group with various clinical presentations and lineage. Non functional PNET (NF-PNET) are incidentally discovered in most cases. This article presents a review of NF-PNET and the case of a patient with this disease, in addition to its diagnosis, clinical presentation, and treatment. Presentation of case: The patient is a 37-year-old asymptomatic man who was sent from his reference unit because of a pancreatic tumor that was visualized incidentally during a laparotomy performed three months before due to an acute abdomen secondary to blunt abdominal trauma. A CT scan was requested that showed a retroperitoneal mass 7.5cm×6.6cm×7cm with infiltration of the duodenal wall. Endoscopy was performed, which reported a duodenal ulcer with nonconclusive histological findings. A percutaneous biopsy was obtained out and a diagnosis of a neuroendocrine tumor was made. Chemotherapy was started because infiltration of the portomesenteric axis was suspected. The patient presented signs of toxicity during his third cycle and therefore was scheduled for exploratory laparotomy. Pancreatoduodenectomy was performed with a histologic diagnosis of a pancreatic neuroendocrine tumor. Discussion: The presentation of a NF-PNET is nonspecific. They continue to be tumors with a low incidence and few studies directed toward early detection and management have been carried out. Currently, CT scans are the studies most used for detection. Conclusion: Surgical treatment is preferred in patients without evidence of unresectability with longer survival. The characteristics of NF-PNETs make their detection difficult and new strategies are needed for early detection and management. New studies in early stages with new cytotoxics or analogs are promising.
Diagnosis and Surgical Treatment of Pancreatic Neuroendocrine Neoplasms

Zhao Xudong,Tian Xiaodong,Yang Yinmo

DOI: https://doi.org/10.3760/cma.j.issn.1007-8118.2017.08.001

2017-01-01

Abstract:Objective To study the diagnosis,treatment and prognostic factors of pancreatic neuroendocrine neoplasms (pNENs).Methods The clinical,pathological and follow-up data of 44 patients with pNENs treated at the Peking University First Hospital from Jan.2007 to Dec.2016 were retrospectively studied.Survival analysis was performed with the Kaplan-Meier method.Results There were 21 male and 23 female patients.The mean age was (54.8 ± 14.0) years.25 patients had non-functional,while 19 had functional pNENs.Curative resection was performed in 40 patients.Neural invasion and intravascular cancer emboli were found in 7 and 5 patients,respectively.The pathologic data showed that the number of patients with G1,G2,G3 were 23 (52.3 ％),15 (34.1％),6 (13.6％),respectively.The number of patients with stage Ⅰ,Ⅱ,Ⅲ,and Ⅳ were 23 (52.3 ％),16 (36.4％),2 (4.5 ％) and 3 (6.8 ％),respectively.The predictive factors on prognosis included curative resection or not,WHO grade,TNM staging,lymph node metastasis and distant metastasis (P ＜ 0.05).Conclusions Curative surgical resection is the first choice of treatment for pNENs.WHO grade,TNM staging,lymph node metastasis and distant metastasis were significantly related to the prognosis of pNENs.
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives

Xian-Bin Zhang,Yi-Bao Fan,Rui Jing,Mikiyas Amare Getu,Wan-Ying Chen,Wei Zhang,Hong-Xia Dong,Tikam Chand Dakal,Akhtar Hayat,Hua-Jun Cai,Milad Ashrafizadeh,A. M. Abd El-Aty,Ahmet Hacimuftuoglu,Peng Liu,Tian-Feng Li,Gautam Sethi,Kwang Seok Ahn,Yavuz Nuri Ertas,Min-Jiang Chen,Jian-Song Ji,Li Ma,Peng Gong

DOI: https://doi.org/10.1186/s40779-024-00535-6

2024-06-06

Military Medical Research

Abstract:Neuroendocrine neoplasms (NENs) are highly heterogeneous and potentially malignant tumors arising from secretory cells of the neuroendocrine system. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are the most common subtype of NENs. Historically, GEP-NENs have been regarded as infrequent and slow-growing malignancies; however, recent data have demonstrated that the worldwide prevalence and incidence of GEP-NENs have increased exponentially over the last three decades. In addition, an increasing number of studies have proven that GEP-NENs result in a limited life expectancy. These findings suggested that the natural biology of GEP-NENs is more aggressive than commonly assumed. Therefore, there is an urgent need for advanced researches focusing on the diagnosis and management of patients with GEP-NENs. In this review, we have summarized the limitations and recent advancements in our comprehension of the epidemiology, clinical presentations, pathology, molecular biology, diagnosis, and treatment of GEP-NETs to identify factors contributing to delays in diagnosis and timely treatment of these patients.

medicine, general & internal
Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms

Anna Battistella,Matteo Tacelli,Paola Mapelli,Marco Schiavo Lena,Valentina Andreasi,Luana Genova,Francesca Muffatti,Francesco De Cobelli,Stefano Partelli,Massimo Falconi

DOI: https://doi.org/10.1080/17474124.2024.2342837

2024-05-04

Expert Review of Gastroenterology & Hepatology

Abstract:Introduction Pancreatic Neuroendocrine Neoplasms (PanNENs) are characterized by a highly heterogeneous clinical and biological behavior, making their diagnosis challenging. PanNENs diagnostic work-up mainly relies on biochemical markers, pathological examination, and imaging evaluation. The latter includes radiological imaging (i.e. computed tomography [CT] and magnetic resonance imaging [MRI]), functional imaging (i.e. 68Gallium [68 Ga]Ga-DOTA-peptide PET/CT and Fluorine-18 fluorodeoxyglucose [18F]FDG PET/CT), and endoscopic ultrasound (EUS) with its associated procedures.

gastroenterology & hepatology
“GERPACYST- The Trial Protocol Of The Prospective, Multicenter, Interdisciplinary German Pancreas Club Cyst Registry”

Kim C. Honselmann,Jonathan Marschner,Anna Staufenbiel,Julia Bertram,Steffen Deichmann,Carsten Engelke,Martha Kirstein,Jens Marquardt,Marko Damm,Fanny Borowitzka,Veit Phillip,Ilaria Pergolini,Felix Harder,Rickmer Braren,Timo Gemoll,Susanne Roth,Sebastian Krug,Christoph Michalski,Robert Jaster,Tobias Keck,Ulrich Wellner,the GERPACYST Study Group

DOI: https://doi.org/10.1101/2024.08.28.24312718

2024-08-29

Abstract:Background Cystic lesions of the pancreas have continued to present a clinical challenge for the past decades now. The increasing rate of detection, the lack of high-quality data on the natural biology of pancreatic cysts and the resulting difficulty to predict malignant transformation in different types of pancreatic cysts make patients with these diseases hard to manage. The German Pancreas Club Cyst Registry (GERPACYST) (DRKS00025927) establishes a platform to discover the natural entity specific biology of pancreatic cysts, in a multicenter manner that should allow to assess risk models for malignancy. Method This manuscript is written according to the SPIRIT guidelines. Ethical approval was obtained from the University of Luebeck (2024-265_1). In GERPACYST patients aged ≥18 years with a pancreatic cyst under surveillance or scheduled for surgery should be enrolled. Participating centers will complete an electronic Case Report Form (eCRF) via REDCap which is designed as a longitudinal study minimizing the input of repeated measures. Changes in patient baseline data, cyst characteristics, both endoscopic and imaging data will be entered typically every 6-12 months during patient follow-up. Biobanking will be performed, when available. Duration of observation per patient is up to a maximum of 20 years or until end of follow-up or death. Discussion GERPACYST will provide a valuable platform for clinical outcomes research. Fundamental factors affecting the development of pancreatic cysts over time will be identified. New research questions might be answered during the study period.
Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Kaizhou Jin,Guopei Luo,Jin Xu,Bo Zhang,Chen Liu,Shurong Ji,Liang Liu,Jiang Long,Quanxing Ni,Xianjun Yu

DOI: https://doi.org/10.3892/ol.2017.5834

2017-01-01

Oncology Letters

Abstract:The aim of the present study was to investigate the clinical, pathological and prognostic characteristics of Chinese patients with resected pancreatic neuroendocrine neoplasms (p-NENs). Data from patients who were surgically treated and pathologically diagnosed with p-NENs at the Department of Pancreatic Oncology of the Fudan University Shanghai Cancer Center (Shanghai, China), between January 2003 and July 2015, were evaluated using univariate and multivariate analyses. A total of 162 patients with p-NENs met the criteria of the present study and were included in the analysis. Patients with poorly differentiated pancreatic neuroendocrine carcinoma (p-NEC) exhibited a significantly increased rate of lymph node metastasis, as compared with patients with grade (G)1/G2 pancreatic neuroendocrine tumors (p-NETs) (62.5 vs. 20.5%, P=0.003). Univariate analysis identified that the following factors led to decreased overall survival (OS): Lymph node metastasis (P=0.001, vs. the absence of lymph node metastasis); distant metastasis (P=0.043, vs. the absence of distant metastasis); resection margin R1/R2 (P=0.030, vs. R0 resection); NEC G3 (P<0.001, vs. NET G1). Following the multivariate analysis, NEC G3 remained a statistically significant risk factor (HR=12.593; 95% CI, 3.476-45.622; P<0.001, vs. NET G1/G2). Furthermore, according to the proliferation marker protein Ki-67 staining index, assigning a grade using the proliferative index (G1, ≤5%; G2, >5-20%; G3, >20%) was more efficient for prognostic stratification compared with the European Neuroendocrine Tumor Society (Berlin, Germany)/World Health Organization (Geneva, Switzerland) 2010 grading classification. The present study indicated that p-NEC was an important predictor of decreased OS in Chinese patients. Furthermore, a Ki-67 staining index of 5% represented a more efficient value for the distinction between G1 and G2.
Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors

Shadin Ghabra,Bhavishya Ramamoorthy,Stephen G Andrews,Samira M Sadowski

DOI: https://doi.org/10.1016/j.suc.2024.02.019

Abstract:Pancreatic neuroendocrine tumors (PNETs) arise from neuroendocrine cells and are a rare class of heterogenous tumors with increasing incidence. The diagnosis, staging, treatment, and prognosis of PNETs depend heavily on identifying the histologic features and biological mechanisms. Here, the authors provide an overview of the diagnostic workup (biomarkers and imaging), grade, and staging of PNETs. The authors also explore associated genetic mutations and molecular pathways and describe updated guidelines on surgical and systemic treatment modalities.
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database

Francesco Panzuto,Stefano Partelli,Davide Campana,Filippo de Braud,Francesca Spada,Mauro Cives,Salvatore Tafuto,Alexia Bertuzzi,Fabio Gelsomino,Francesca Bergamo,Stefano Marcucci,Laura Mastrangelo,Sara Massironi,Marialuisa Appetecchia,Angelina Filice,Giuseppe Badalamenti,Mirco Bartolomei,Vito Amoroso,Luca Landoni,Maria Grazia Rodriquenz,Monica Valente,Annamaria Colao,Andrea Isidori,Giuseppe Fanciulli,Roberto Bollina,Michele Ciola,Giovanni Butturini,Riccardo Marconcini,Emanuela Arvat,Saverio Cinieri,Rossana Berardi,Sergio Baldari,Ferdinando Riccardi,Chiara Spoto,Dario Giuffrida,Domenico Gattuso,Diego Ferone,Maria Rinzivillo,Emilio Bertani,Annibale Versari,Alessandro Zerbi,Giuseppe Lamberti,Eleonora Lauricella,Sara Pusceddu,Nicola Fazio,Elisabetta Dell’Unto,Marco Marini,Massimo Falconi

DOI: https://doi.org/10.1007/s12020-023-03649-4

2024-01-05

Endocrine

Abstract:Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical behaviors. Large databases like the Surveillance, Epidemiology, and End Results (SEER) program and national NEN registries have provided significant epidemiological knowledge, but they have limitations given the recent advancements in NEN diagnostics and treatments. For instance, newer imaging techniques and therapies have revolutionized NEN management, rendering older data less representative. Additionally, crucial parameters, like the Ki67 index, are missing from many databases. Acknowledging these gaps, the Italian Association for Neuroendocrine Tumors (Itanet) initiated a national multicenter prospective database in 2019, aiming to gather data on newly-diagnosed gastroenteropancreatic neuroendocrine (GEP) NENs. This observational study, coordinated by Itanet, includes patients from 37 Italian centers. The database, which is rigorously maintained and updated, focuses on diverse parameters including age, diagnostic techniques, tumor stage, treatments, and survival metrics. As of October 2023, data from 1,600 patients have been recorded, with an anticipation of reaching 3600 by the end of 2025. This study aims at understanding the epidemiology, clinical attributes, and treatment strategies for GEP-NENs in Italy, and to introduce the Itanet database project. Once comprehensive follow-up data will be acquired, the goal will be to discern predictors of treatment outcomes and disease prognosis. The Itanet database will offer an unparalleled, updated perspective on GEP-NENs, addressing the limitations of older databases and aiding in optimizing patient care.

endocrinology & metabolism
AB086. P058. Current Status of Pancreatic Cystic Neoplasm: Diagnosis and Treatment a Multi-Institution Retrospective Study in China

Yadong Xu,Ji Li,Xin Wang,Gang Li,Gang Zhao,Lei Wang,Jun Cao,Kuirong Jiang,Zheng Wang,Xueli Bai,Yongsheng Yang,Chunhui Yuan,Xiaodong Tian,Xiaowu Xu,Fabao Liu,Xue’e Bai,Rui Kong,Wenchuan Wu,Wenhui Lou

DOI: https://doi.org/10.21037/apc.2018.ab086

2018-01-01

Annals of Pancreatic Cancer

Abstract:Background: The aims of this study were to introduce our current situation of diagnosis and treatment of pancreatic cystic neoplasm (PCN) in China. Methods: A total of 2,251 PCN patients who underwent surgical resection from January 2006 to December 2016 in 16 institutions were retrospectively analyzed. Results: The male to female ratio was 1 to 2.4, and the age at diagnosis was 47.5 years (range, 8–89 years). The preoperative diagnostic coincidence rate of solid pseudo-papillary tumor (SPT) was 48.5%, serous cystic neoplasm (SCN) was 13.7%, intraductal papillary mucinous neoplasm (IPMN) was 49.7, mucinous cystic neoplasm (MCN) was 15.6% respectively and the PCN was 33%. SPT, SCN, IPMN, MCN were 713 cases, 678 cases, 495 cases, 365 cases respectively by pathologically diagnosed, and the malignant transformation rate was 12.3%,0.6%,32.1%,10.4% respectively. The rate of postoperative complications was 46%, the pancreatic fistula (PF) and delayed gastric emptying (DGE) were the main complications. The tumor marker, such as CEA, CA19-9, CA125, was significantly increased in the malignant group. Conclusions: SPT maybe the most common tumor in all PCN in China. Improving the accuracy of subtype (especially the SCN and the MCN) diagnosis preoperatively can avoid unnecessary surgery.
Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

Aldo Scarpa,David K. Chang,Katia Nones,Vincenzo Corbo,Ann-Marie Patch,Peter Bailey,Rita T. Lawlor,Amber L. Johns,David K. Miller,Andrea Mafficini,Borislav Rusev,Maria Scardoni,Davide Antonello,Stefano Barbi,Katarzyna O. Sikora,Sara Cingarlini,Caterina Vicentini,Skye McKay,Michael C. J. Quinn,Timothy J. C. Bruxner,Angelika N. Christ,Ivon Harliwong,Senel Idrisoglu,Suzanne McLean,Craig Nourse,Ehsan Nourbakhsh,Peter J. Wilson,Matthew J. Anderson,J. Lynn Fink,Felicity Newell,Nick Waddell,Oliver Holmes,Stephen H. Kazakoff,Conrad Leonard,Scott Wood,Qinying Xu,Shivashankar Hiriyur Nagaraj,Eliana Amato,Irene Dalai,Samantha Bersani,Ivana Cataldo,Angelo P. Dei Tos,Paola Capelli,Maria Vittoria Davì,Luca Landoni,Anna Malpaga,Marco Miotto,Vicki L. J. Whitehall,Barbara A. Leggett,Janelle L. Harris,Jonathan Harris,Marc D. Jones,Jeremy Humphris,Lorraine A. Chantrill,Venessa Chin,Adnan M. Nagrial,Marina Pajic,Christopher J. Scarlett,Andreia Pinho,Ilse Rooman,Christopher Toon,Jianmin Wu,Mark Pinese,Mark Cowley,Andrew Barbour,Amanda Mawson,Emily S. Humphrey,Emily K. Colvin,Angela Chou,Jessica A. Lovell,Nigel B. Jamieson,Fraser Duthie,Marie-Claude Gingras,William E. Fisher,Rebecca A. Dagg,Loretta M. S. Lau,Michael Lee,Hilda A. Pickett,Roger R. Reddel,Jaswinder S. Samra,James G. Kench,Neil D. Merrett,Krishna Epari,Nam Q. Nguyen,Nikolajs Zeps,Massimo Falconi,Michele Simbolo,Giovanni Butturini,George Van Buren,Stefano Partelli,Matteo Fassan,Kum,Anthony J. Gill,David A. Wheeler,Richard A. Gibbs,Elizabeth A. Musgrove,Claudio Bassi,Giampaolo Tortora,Paolo Pederzoli,John V. Pearson,Nicola Waddell,Andrew V. Biankin,Sean M. Grimmond

DOI: https://doi.org/10.1038/nature21063

IF: 64.8

2017-01-01

Nature

Abstract:Neuroendocrine tumours (NETs) may arise throughout the body and are a highly heterogeneous, relatively rare class of neoplasms difficult to study also for the lack of disease models. Despite this, knowledge on their molecular alterations has expanded in the latest years, also building from genetic syndromes causing their onset. Pancreatic NETs (PanNETs) have been among the most studied, and research so far has outlined a series of recurring features, as inactivation of MEN1, VHL, TSC1/2 genes and hyperactivation of the PI3K/mTOR pathway. Next-generation sequencing has added new information by showing the key role of alternative lengthening of telomeres, driven in a fraction of PanNETs by inactivation of ATRX/DAXX. Despite this accumulation of knowledge, single studies often relied on few cases or were limited to the DNA, RNA, protein or epigenetic level with lack of integrative analysis. The International Cancer Genome Consortium aimed at removing these barriers through a strict process of data and samples collection, to produce whole-genome integrated analyses for many tumour types. The results of this effort on PanNETs have been recently published and, while confirming previous observations provide a first snapshot of how heterogeneous is the combination of genetic alterations that drive this tumour type, yet converging into four pathways whose alteration has been enriched by newly discovered mechanisms. While calling for further integration of genetic and epigenetic analyses, these data allow to reconcile previous findings in a defined frame and may provide clinical research with markers for patients stratification and to guide targeted therapy decisions.
Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

Kevin C Yang,Steve E Kalloger,John J Aird,Michael K C Lee,Christopher Rushton,Karen L Mungall,Andrew J Mungall,Dongxia Gao,Christine Chow,Jing Xu,Joanna M Karasinska,Shane Colborne,Steven J M Jones,Jörg Schrader,Ryan D Morin,Jonathan M Loree,Marco A Marra,Daniel J Renouf,Gregg B Morin,David F Schaeffer,Sharon M Gorski,Kevin C. Yang,Steve E. Kalloger,John J. Aird,Michael K.C. Lee,Karen L. Mungall,Andrew J. Mungall,Joanna M. Karasinska,Steven J.M. Jones,Ryan D. Morin,Jonathan M. Loree,Marco A. Marra,Daniel J. Renouf,Gregg B. Morin,David F. Schaeffer,Sharon M. Gorski

DOI: https://doi.org/10.1016/j.celrep.2021.109817

IF: 8.8

2021-10-01

Cell Reports

Abstract:Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous. Here, we use a multi-omics approach to uncover the molecular factors underlying this heterogeneity. Transcriptomic analysis of 84 PNEN specimens, drawn from two cohorts, is substantiated with proteomic profiling and identifies four subgroups: Proliferative, PDX1-high, Alpha cell-like and Stromal/Mesenchymal. The Proliferative subgroup, consisting of both well- and poorly differentiated specimens, is associated with inferior overall survival probability. The PDX1-high and Alpha cell-like subgroups partially resemble previously described subtypes, and we further uncover distinctive metabolism-related features in the Alpha cell-like subgroup. The Stromal/Mesenchymal subgroup exhibits molecular characteristics of YAP1/WWTR1(TAZ) activation suggestive of Hippo signaling pathway involvement in PNENs. Whole-exome sequencing reveals subgroup-enriched mutational differences, supported by activity inference analysis, and identifies hypermorphic proto-oncogene variants in 14.3% of sequenced PNENs. Our study reveals differences in cellular signaling axes that provide potential directions for PNEN patient stratification and treatment strategies.

cell biology
RETRACTED: Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database (Retracted Article)

Gang Li

DOI: https://doi.org/10.1155/2022/3689895

IF: 2.809

2022-01-01

Computational and Mathematical Methods in Medicine

Abstract:Background. The incidence of nonfunctional pancreatic neuroendocrine neoplasms (NF-pNENs) has been increasing annually. This study is aimed at investigating the clinicopathological characteristics and high-risk factors of NF-pNENs and the influence of surgical treatment on the prognosis of NF-pNEN patients with liver metastases. Methods. pNEN patients in this study were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. This study analyzed patients diagnosed with NF-pNENs from 2000 to 2017 who met the inclusion criteria. A retrospective analysis of the clinicopathological characteristics of NF-pNEN patients was conducted. Kaplan-Meier method was used to calculate the survival time. A multivariate Cox regression model was used to analyze the survival outcomes and risk factors. Results. From 2000 to 2017, the SEER database registered 10576 patients with pNENs and 1774 patients with liver metastases. Cox analysis revealed that age, sex, primary site, grade, tumor stage, surgery, tumor size, and liver metastasis were risk factors of prognosis, with grade being the most influential index. Patients with NF-pNENs with liver metastasis and no metastasis had different primary site, grade, and tumor size. In general, a higher grade was associated with a larger tumor and a greater risk of liver metastasis. Meanwhile, patients with liver metastasis showed that those with tumors originated from the tail of the pancreas had better prognoses than those with tumors originated from other parts. Surgical treatment can improve the prognosis of patients with liver metastases, despite the tumor grade. Conclusions. The incidence of pNENs has been increasing annually, and the liver has been the most common site of metastasis. Liver metastasis in patients with NF-pNENs, related to tumor size and grade, affected their long-term survival. Surgery significantly improved the prognosis of patients with liver metastases secondary to NF-pNENs with different grades.
Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology

Mark Kidd,Irvin M Modlin,Lisa Bodei,Ignat Drozdov

DOI: https://doi.org/10.1016/j.jcmgh.2014.12.008

2015-01-12

Abstract:Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), considered a heterogeneous neoplasia, exhibit ill-defined pathobiology and protean symptomatology and are ubiquitous in location. They are difficult to diagnose, challenging to manage, and outcome depends on cell type, secretory product, histopathologic grading, and organ of origin. A morphologic and molecular genomic review of these lesions highlights tumor characteristics that can be used clinically, such as somatostatin-receptor expression, and confirms features that set them outside the standard neoplasia paradigm. Their unique pathobiology is useful for developing diagnostics using somatostatin-receptor targeted imaging or uptake of radiolabeled amino acids specific to secretory products or metabolism. Therapy has evolved via targeting of protein kinase B signaling or somatostatin receptors with drugs or isotopes (peptide-receptor radiotherapy). With DNA sequencing, rarely identified activating mutations confirm that tumor suppressor genes are relevant. Genomic approaches focusing on cancer-associated genes and signaling pathways likely will remain uninformative. Their uniquely dissimilar molecular profiles mean individual tumors are unlikely to be easily or uniformly targeted by therapeutics currently linked to standard cancer genetic paradigms. The prevalence of menin mutations in pancreatic NEN and P27KIP1 mutations in small intestinal NEN represents initial steps to identifying a regulatory commonality in GEP-NEN. Transcriptional profiling and network-based analyses may define the cellular toolkit. Multianalyte diagnostic tools facilitate more accurate molecular pathologic delineations of NEN for assessing prognosis and identifying strategies for individualized patient treatment. GEP-NEN remain unique, poorly understood entities, and insight into their pathobiology and molecular mechanisms of growth and metastasis will help identify the diagnostic and therapeutic weaknesses of this neoplasia.
New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Feng Yin,Zi-Hao Wu,Jin-Ping Lai

DOI: https://doi.org/10.3748/wjg.v28.i17.1751

IF: 5.374

2022-05-07

World Journal of Gastroenterology

Abstract:Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare epithelial neoplasms derived from pluripotent endocrine cells along the gastrointestinal tract and pancreas. GEP-NENs are classified into well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Despite overlapping morphological features, GEP-NENs vary in molecular biology, epigenetic, clinical behavior, treatment response, and prognosis features and remain an unmet clinical challenge. In this review, we introduce recent updates on the histopathologic classification, including the tumor grading and staging system, molecular genetics, and systemic evaluation of the diagnosis and treatment of GEP-NENs at different anatomic sites, together with some insights into the diagnosis of challenging and unusual cases. We also discuss the application of novel therapeutic approaches for GEP-NENs, including peptide receptor radionuclide therapy, targeted therapy, and immunotherapy with immune checkpoint inhibitors. These findings will help improve patient care with precise diagnosis and individualized treatment of patients with GEP-NENs.

gastroenterology & hepatology
Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies

Jemma Arakelyan,Davit Zohrabyan,Philip A. Philip

DOI: https://doi.org/10.1002/cncr.33354

IF: 6.9209

2020-12-03

Cancer

Abstract:Pancreatic neuroendocrine neoplasms (panNENs) are the second most common epithelial tumors of the pancreas. Despite improvements in prognostic grading and staging systems, it remains a challenge to predict the clinical behavior of panNENs and the response to specific therapies given the high degree of heterogeneity of these tumors. Most panNENs are nonfunctional and present as advanced disease. However, systemic therapies provide modest benefits. Therefore, there is a need for predictive biomarkers to develop personalized treatment and to advance new drug development. The somatostatin receptors remain the only clinically established prognostic and predictive biomarkers in panNENs. Oncogenic drivers are at a very low frequency. Commonly mutated genes in panNENs include MEN1, chromatin remodeling genes (DAXX and ATRX), and mammalian target of rapamycin pathway genes. In contrast, poorly differentiated neuroendocrine carcinomas (panNECs), which carry a very poor prognosis, have distinctive mutations in certain genes (eg, RB1 and p53). Ongoing research to integrate epigenomics will provide tremendous opportunities to improve current understanding of the clinical heterogeneity of pancreatic neuroendocrine tumors and provide invaluable insight into the biology of these tumors, new drug development, and establishing personalized therapies.

oncology
Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Kaizhou Jin,Jin Xu,Jie Chen,Minhu Chen,Rufu Chen,Ye Chen,Zhiyu Chen,Bin Cheng,Yihebali Chi,Shi-Ting Feng,Deliang Fu,Baohua Hou,Dan Huang,Heguang Huang,Qiang Huang,Jie Li,Ying Li,Houjie Liang,Rong Lin,An'an Liu,Jixi Liu,Xubao Liu,Ming Lu,Jie Luo,Gang Mai,Quanxing Ni,Meng Qiu,Chenghao Shao,Baiyong Shen,Weiqi Sheng,Jian Sun,Chunlu Tan,Huangying Tan,Qiyun Tang,Yingmei Tang,Xiaodong Tian,Danian Tong,Xiaohong Wang,Jian Wang,Jie Wang,Wei Wang,Yu Wang,Zheng Wu,Ling Xue,Qiang Yan,Ning Yang,Yinmo Yang,Zhiying Yang,Xiaoyi Yin,Chunhui Yuan,Shan Zeng,Renchao Zhang,Xianjun Yu

DOI: https://doi.org/10.3892/ijo.2016.3711

Abstract:Pancreatic neuroendocrine neoplasms (p-NENs) are slowly growing tumors with frequent liver metastasis. There is a variety of approaches to treat non-functional p-NENs with synchronous liver metastasis (LM) which complicates the determination of optimal treatment. Based on updated literature review, we discussed the treatment strategy determinants for p-NEN with LM. According to the resectability of primary tumor, the WHO 2010 grade classification and the radiological type of liver metastasis, the CSNET group reached agreements on a number of issues, including the following. Prior to treatment, biopsy is required to confirm pathology. Liver biopsy is important for more accurate grading of tumor and percutaneous core needle biopsy is more available than EUS-FNA. In patients with unresectable primary, surgical resection for liver-metastatic lesions should be avoided. Curative surgery is recommended for G1/G2 p-NET with type I LM and R1 resection also seems to improve overall survival rate. Cytoreductive surgery is recommended for G1/G2 p-NET with type II LM in select patients, and should meet stated requirements. Surgical resection for G1/G2 p-NET with type III LM and p-NEC with LM should be avoided, and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM. Liver transplantation may be an option in highly select patients. In addition, the optimal time for surgical approach is still required for more evidence.

Cystic Pancreatic Neuroendocrine Neoplasms : A Multicenter International Cohort Study

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study

Clinical Features Of Patients With Pancreatic Neuroendocrine Neoplasms: A Retrospective Analysis Of 61 Cases In A Cancer Center

Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature

Diagnosis and Surgical Treatment of Pancreatic Neuroendocrine Neoplasms

Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives

Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms

“GERPACYST- The Trial Protocol Of The Prospective, Multicenter, Interdisciplinary German Pancreas Club Cyst Registry”

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors

Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database

AB086. P058. Current Status of Pancreatic Cystic Neoplasm: Diagnosis and Treatment a Multi-Institution Retrospective Study in China

Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

RETRACTED: Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database (Retracted Article)

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)